Insulet (NASDAQ:PODD) Price Target Lowered to $150.00 at UBS Group

Insulet (NASDAQ:PODD) had its price objective reduced by stock analysts at UBS Group from $174.00 to $150.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group’s target price indicates a potential upside of 8.56% from the stock’s previous close.

Several other analysts also recently issued reports on the stock. Royal Bank Of Canada cut their target price on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday. Canaccord Genuity Group set a $179.00 price target on Insulet in a report on Thursday. William Blair assumed coverage on Insulet in a research report on Wednesday, May 20th. They set an “outperform” rating on the stock. Citigroup increased their price objective on Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Finally, Wall Street Zen upgraded Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Fifteen equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $201.40.

Insulet Trading Up 3.7%

Shares of NASDAQ:PODD traded up $4.91 during midday trading on Thursday, reaching $138.17. The company had a trading volume of 2,320,751 shares, compared to its average volume of 1,305,839. The company has a fifty day simple moving average of $155.56 and a two-hundred day simple moving average of $195.01. The firm has a market cap of $9.57 billion, a price-to-earnings ratio of 32.14, a price-to-earnings-growth ratio of 1.16 and a beta of 1.10. Insulet has a 1-year low of $126.40 and a 1-year high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same period last year, the company posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts predict that Insulet will post 6.45 earnings per share for the current year.

Insider Transactions at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.36% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PODD. State Street Corp grew its position in Insulet by 2.1% during the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after buying an additional 65,317 shares in the last quarter. Geode Capital Management LLC raised its holdings in Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares in the last quarter. Invesco Ltd. lifted its position in shares of Insulet by 10.5% in the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after acquiring an additional 141,167 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after acquiring an additional 1,011,369 shares during the period. Finally, Norges Bank acquired a new stake in shares of Insulet during the 4th quarter worth approximately $300,794,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported second-quarter adjusted earnings of $1.66 per share and revenue of $801.7 million, exceeding analyst estimates of $1.47 and $787.4 million, respectively. Revenue increased 23.5% year over year. Reuters earnings and outlook report
• Positive Sentiment: Management said overall growth remains intact, supported by Omnipod adoption and expansion in the broader insulin-pump market, although the company is resetting expectations for Type 2 customers. Insulet earnings call summary
• Positive Sentiment: Benchmark and Stifel retained “buy” ratings while lowering their price targets to $185 and $180, respectively, implying substantial potential upside from recent levels.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.